



PRESS RELEASE

Cancer treatments: AREVA and INSERM sign a research agreement

Paris, January 11, 2010

AREVA and its subsidiary AREVA Med today announced the signature of a cooperative research agreement with the French National Institute of Health and Medical Research (INSERM) for the development of innovative cancer treatments.

The group has developed a process to extract Lead-212 from thorium derived from past industrial activities. Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments. It is used in radioimmunotherapy to pinpoint and destroy cancer cells.

The AREVA/INSERM research program will be chaired by Dr. Jean-Pierre Pouget, Head of the Radiobiology Department at the Montpellier Cancer Research Institute under the direction of Dr. André Pèlegrin.

“We are delighted to be working with INSERM. This agreement is further proof of AREVA’s desire to step up its activities in the field of nuclear medicine and use its know-how and technology to innovate by joining forces with the world’s leading laboratories”, said Patrick Bourdet, CEO of AREVA Med, speaking at the signing ceremony.

In nuclear medicine, the development of new treatments depends on isotope availability. In March 2010, AREVA Med announced the construction of a Lead-212 industrial production plant in the Limousin region (France) that will allow the creation of new targeted therapies for patients.

More information at www.aveva.com and www.avevamed.com

Press Office

Patricia Marie
Pauline Briand
Fleur Floquet-Daubigeon
T: +33 (0) 1 34 96 12 15
F: +33 (0) 1 34 96 16 54
press@aveva.com

Investor Relations

Marie de Scorbiac
marie.descorbiac@aveva.com
T: +33 (0) 1 34 96 05 97

MORE ABOUT

AREVA supplies solutions for carbon-free power generation. Its expertise and know-how in this field are setting the standard, and its responsible development is anchored in a process of continuous improvement. As the global nuclear industry leader, AREVA’s unique integrated offer to utilities covers every stage of the fuel cycle, nuclear reactor design and construction, and related services. The group is also expanding considerably in renewable energies – wind, solar, bioenergies, hydrogen and storage – to be one of the top three in this sector worldwide in 2012. Every day, AREVA’s 48,000 employees cultivate the synergies between these two major carbon-free offers, helping to supply safer, cleaner and more economical energy to the greatest number of people.